SG11202101779RA - Multi-chain chimeric polypeptides and uses thereof - Google Patents

Multi-chain chimeric polypeptides and uses thereof

Info

Publication number
SG11202101779RA
SG11202101779RA SG11202101779RA SG11202101779RA SG11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA
Authority
SG
Singapore
Prior art keywords
chimeric polypeptides
chain chimeric
chain
polypeptides
chimeric
Prior art date
Application number
SG11202101779RA
Inventor
Hing Wong
Original Assignee
Hcw Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hcw Biologics Inc filed Critical Hcw Biologics Inc
Publication of SG11202101779RA publication Critical patent/SG11202101779RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
SG11202101779RA 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof SG11202101779RA (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862725010P 2018-08-30 2018-08-30
US201862725043P 2018-08-30 2018-08-30
US201862724969P 2018-08-30 2018-08-30
US201862746832P 2018-10-17 2018-10-17
US201862749007P 2018-10-22 2018-10-22
US201862749506P 2018-10-23 2018-10-23
US201962816683P 2019-03-11 2019-03-11
US201962817230P 2019-03-12 2019-03-12
US201962817241P 2019-03-12 2019-03-12
US201962881088P 2019-07-31 2019-07-31
PCT/US2019/048881 WO2020047299A1 (en) 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
SG11202101779RA true SG11202101779RA (en) 2021-03-30

Family

ID=67928938

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101779RA SG11202101779RA (en) 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof

Country Status (11)

Country Link
US (8) US11518792B2 (en)
EP (2) EP4659757A3 (en)
JP (3) JP7397874B2 (en)
KR (2) KR20250160211A (en)
CN (1) CN112996805A (en)
AU (2) AU2019328290B2 (en)
CA (1) CA3108949A1 (en)
IL (1) IL280918B2 (en)
SG (1) SG11202101779RA (en)
TW (1) TWI851594B (en)
WO (1) WO2020047299A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Interleukin-18 variants and methods of use
CN120535649A (en) 2018-08-30 2025-08-26 免疫生物公司 Single-chain chimeric polypeptides and uses thereof
US11730762B2 (en) 2018-08-30 2023-08-22 HCW Biologics, Inc. Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3112989A1 (en) 2018-09-27 2020-04-02 Xilio Development, Inc. Masked cytokine polypeptides
CN114269903B (en) 2019-06-21 2025-11-25 免疫生物公司 Multi-chain chimeric peptides and their uses
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
JP2023513573A (en) 2020-02-11 2023-03-31 エイチシーダブリュー バイオロジックス インコーポレイテッド Methods of treating age-related and inflammatory diseases
AU2021219720B2 (en) * 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
JP7734693B2 (en) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド Anti-CD26 proteins and their uses
IL298608A (en) * 2020-06-01 2023-01-01 Hcw Biologics Inc Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
USD986799S1 (en) * 2020-09-11 2023-05-23 Wind Craft Aviation Inc. Aircraft
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc Tumor-specific cleavable linkers
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
US11672844B2 (en) 2021-02-17 2023-06-13 Cura Therapeutics, Inc. Method of treating or ameliorating a pathogenic infection by administering an interleukin-2/TGF-β receptor fusion polypeptide
EP4378960A4 (en) * 2021-07-30 2025-07-30 Qure Biotechnology Shanghai Co Ltd Antigen targeting, anti-CD16A, and immune effector cells for activation of a trifunctional fusion protein and application thereof
US20230125173A1 (en) * 2021-08-11 2023-04-27 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
CN114042154B (en) * 2021-12-14 2024-08-16 澳门大学 Application of pharmaceutical composition in preparation of anti-tumor combined therapeutic drug
CN118591563A (en) * 2022-01-14 2024-09-03 盛禾(中国)生物制药有限公司 A bispecific antibody combining B7H3 and NKP30 and its application
CA3245338A1 (en) * 2022-03-02 2023-09-07 Immunitybio, Inc. Method of treating pancreatic cancer
US20240075141A1 (en) 2022-03-18 2024-03-07 WUGEN, Inc. Chimeric receptor constructs for nk cells
US20230330228A1 (en) 2022-03-22 2023-10-19 WUGEN, Inc. Hybrid promoters, vectors containing same and methods of use
WO2024004869A1 (en) * 2022-06-29 2024-01-04 メスキュージェナシス株式会社 Peptide and assembly or composition containing said peptide
WO2025054489A1 (en) * 2023-09-08 2025-03-13 The Regents Of The University Of California Chimeric antigen receptors with card domains
AU2024374454A1 (en) * 2023-10-31 2026-03-05 Immunitybio, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
CN117924505B (en) * 2024-03-25 2024-09-13 青岛宝迈得生物科技有限公司 A recombinant HDAC2 protein monoclonal antibody and its application
WO2026043909A1 (en) * 2024-08-19 2026-02-26 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2026043906A1 (en) * 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN120289652B (en) * 2025-04-16 2026-02-13 广东拓普灵生物医药科技有限公司 A method for preparing NK cells and its application in tumor immunotherapy

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JP4361133B2 (en) 1994-07-11 2009-11-11 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Methods and compositions for specific coagulation of the vasculature
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP2001206899A (en) 1999-11-18 2001-07-31 Japan Tobacco Inc HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF
US20010044427A1 (en) 1999-12-20 2001-11-22 Sidney Mazel Pharmaceutical kit
ES2373966T3 (en) 2000-02-24 2012-02-10 Philogen S.P.A. COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF ANGIOGENESIS IN PATHOLOGICAL INJURIES.
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
DK1345969T3 (en) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28 antibody
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
AU2002355955A1 (en) 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003104425A2 (en) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ES2524325T3 (en) * 2002-07-15 2014-12-05 Board Of Regents, The University Of Texas System Selected antibodies that bind to aminophospholipids and their use in cancer treatment
KR20050058486A (en) 2002-08-30 2005-06-16 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 Human antihuman interleukin-6 antibody and fragment of the antibody
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
JP4511943B2 (en) 2002-12-23 2010-07-28 ワイス エルエルシー Antibody against PD-1 and use thereof
ES2729974T3 (en) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Specific antibody of human PD-1 and CD3
WO2004076488A1 (en) 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
EP1608315A4 (en) 2003-03-21 2008-07-16 Wyeth Corp Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
RU2369636C2 (en) 2003-05-23 2009-10-10 Уайт Ligand gitr and molecules and antibodies bound with ligand gitr, and versions of their application
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
JP2005124568A (en) 2003-10-01 2005-05-19 Junichi Masuyama Cell activation method, cell production method using the same, and pharmaceutical composition
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ATE531732T1 (en) 2004-03-30 2011-11-15 Yissum Res Dev Co BI-SPECIFIC ANTIBODIES TARGETING CELLS INVOLVED IN ALLERGIC-TYPE REACTIONS, COMPOSITIONS AND USES THEREOF
BRPI0607639B1 (en) 2005-02-08 2022-04-05 Genzyme Corporation Human antibody molecules or antigen-binding fragments thereof that bind and neutralize tgf-beta1, 2 and 3, their use and pharmaceutical composition
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
EP2399594B1 (en) 2005-03-17 2019-08-14 UCL Business PLC Tumour cell-activated Natural Killer cells
CN100509849C (en) 2005-04-07 2009-07-08 苏州大学 Soluble human CD28 molecule detection kit and use thereof
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
KR100990027B1 (en) 2005-04-26 2010-10-26 화이자 인코포레이티드 P-cadherin antibody
ES2341126T3 (en) 2005-05-11 2010-06-15 Philogen S.P.A. L19 ANTIBODY FUSION PROTEIN AGAINST ED-B AND INTERLEUCIN FIBRONECTINE 12.
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
ES2456296T3 (en) 2008-03-27 2014-04-21 Zymogenetics, Inc. Compositions and procedures for inhibiting PDGFR beta and VEGF-A
CN110372792A (en) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 Inhibit the stabilization and soluble antibodies of VEGF
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
NZ717213A (en) 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
DE102009045006A1 (en) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases
KR20140015139A (en) 2009-10-15 2014-02-06 애브비 인코포레이티드 Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
AU2011215750A1 (en) 2010-02-11 2012-08-23 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-CD200 antibodies
JP6060073B2 (en) 2010-04-08 2017-01-11 ジェイエヌ バイオサイエンシーズ エルエルシー Antibody against CD122
TWI629483B (en) 2010-06-11 2018-07-11 協和醱酵麒麟有限公司 anti-TIM-3 antibody
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012034668A (en) 2010-08-12 2012-02-23 Tohoku Univ Fragment of humanized anti-egfr antibody substituted-lysine variable region, and use thereof
CN107880136B (en) * 2010-09-21 2021-11-12 阿尔托生物科学有限公司 Multimeric IL-15 soluble fusion molecules and methods of making and using the same
MX344268B (en) 2010-10-11 2016-12-09 Abbvie Inc * Processes for purification of proteins.
CN102153653B (en) 2010-12-30 2012-08-15 厦门大学 Fusion protein of tumor blood vessel targeted polypeptide and tissue factor and preparation method thereof
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
TWI631136B (en) 2011-04-19 2018-08-01 莫瑞麥克製藥公司 Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
TR201808018T4 (en) 2011-04-25 2018-06-21 Daiichi Sankyo Co Ltd Anti-B7-H3 antibody.
WO2012160448A2 (en) 2011-05-25 2012-11-29 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory disorders
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
WO2012170470A1 (en) 2011-06-06 2012-12-13 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
EP2723377B1 (en) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CN104053672A (en) 2011-11-11 2014-09-17 瑞纳神经科学公司 Antibodies specific for Trop-2 and their uses
GB2513793B (en) 2012-01-26 2016-11-02 Nugen Tech Inc Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
CA2866378A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
KR101535341B1 (en) 2012-07-02 2015-07-13 한화케미칼 주식회사 Novel monoclonal antibody that specifically binds to DLL4 and use thereof
SG11201408526SA (en) 2012-08-08 2015-03-30 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
WO2014026054A2 (en) 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CA2879494A1 (en) 2012-08-28 2014-03-06 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
CN109180815B (en) 2012-11-20 2022-06-21 赛诺菲 anti-CEACAM 5 antibodies and uses thereof
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
JP2015030666A (en) 2013-07-31 2015-02-16 学校法人順天堂 Anti-human cd26 monoclonal antibodies and antigen-binding fragments thereof
CN103709251B (en) 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 Total man source anti-CD 26 antibodies and application thereof
KR102127408B1 (en) 2014-01-29 2020-06-29 삼성전자주식회사 Anti-Her3 scFv fragment and Bispecific anti-c-Met/anti-Her3 antibodies comprising the same
ME03489B (en) 2014-01-31 2020-01-20 Novartis Ag ANTIBODY MOLECULES ON TEAM-3 AND THEIR USES
EP3103811A4 (en) 2014-02-03 2017-11-29 National Cancer Center Anti-tissue factor monoclonal antibody
FR3021970B1 (en) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES
JO3664B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-tigit antibodies
ES2774380T3 (en) 2014-08-29 2020-07-20 Hoffmann La Roche Tumor-directed IL-2 variant immunocytokine polytherapy and antibodies to human PD-L1
EP3237450B1 (en) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
KR20170138494A (en) 2015-04-17 2017-12-15 엘살리스 비오떼끄 Anti-TYR03 antibodies and uses thereof
KR101778439B1 (en) 2015-04-27 2017-09-14 울산대학교 산학협력단 composition for improving immunity and anti-cancer activity comprising natural killer cell activator
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
TW201713699A (en) 2015-08-06 2017-04-16 新加坡科技研究局 Interleukin 2 receptor β (IL2Rβ) / common γ chain antibody
KR20180061226A (en) 2015-09-11 2018-06-07 와이즈에이씨가부시키가이샤 Composition for the treatment of cancer combined with an anti-CD26 antibody and another anticancer agent
CN113912724B (en) 2015-09-25 2025-03-14 豪夫迈·罗氏有限公司 Anti-TIGIT antibodies and methods of use
WO2017083612A1 (en) 2015-11-13 2017-05-18 Dana-Farber Cancer Institute, Inc. An nkg2d-ig fusion protein for cancer immunotherapy
EA201891724A1 (en) 2016-02-17 2019-01-31 Новартис Аг ANTIBODIES TO TGF-BETA2
IL296874A (en) 2016-03-01 2022-11-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific to human poliovirus receptor (pvr)
WO2017189526A1 (en) 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
CA3039532A1 (en) 2016-10-05 2018-04-12 University Of Central Florida Research Foundation, Inc. Methods and compositions related to nk cell and anti-pdl1 cancer therapies
WO2018075989A1 (en) * 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules
WO2018129007A1 (en) 2017-01-03 2018-07-12 Bioatla Llc Protein therapeutics for treatment of senescent cells
TW202506185A (en) 2017-01-20 2025-02-16 法商賽諾菲公司 Anti-tgf-beta antibodies and their use
JP2020510657A (en) 2017-02-28 2020-04-09 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ Combination of anti-CD16A antibody with cytokine
AU2018231170B2 (en) 2017-03-06 2020-07-16 Altor Bioscience Corporation IL-15-based fusions to IL-12 and IL-18
AU2018244221B2 (en) 2017-03-27 2021-06-03 Nantcell, Inc. ANK and IL-12 compositions and methods
EP3421607A1 (en) 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
CA3074635A1 (en) 2017-08-28 2019-03-07 Altor Bioscience Llc Il-15-based fusions to il-7 and il-21
US11730762B2 (en) 2018-08-30 2023-08-22 HCW Biologics, Inc. Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide
CN120535649A (en) 2018-08-30 2025-08-26 免疫生物公司 Single-chain chimeric polypeptides and uses thereof
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN114269903B (en) 2019-06-21 2025-11-25 免疫生物公司 Multi-chain chimeric peptides and their uses
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
JP2023513573A (en) 2020-02-11 2023-03-31 エイチシーダブリュー バイオロジックス インコーポレイテッド Methods of treating age-related and inflammatory diseases
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
JP7734693B2 (en) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド Anti-CD26 proteins and their uses
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders

Also Published As

Publication number Publication date
CN112996805A (en) 2021-06-18
KR20250160211A (en) 2025-11-11
US20230128292A1 (en) 2023-04-27
NZ772550A (en) 2025-08-29
JP7397874B2 (en) 2023-12-13
US20240132561A1 (en) 2024-04-25
EP4659757A3 (en) 2026-01-14
US12509494B2 (en) 2025-12-30
WO2020047299A1 (en) 2020-03-05
US12398186B2 (en) 2025-08-26
EP4659757A2 (en) 2025-12-10
US20210070826A1 (en) 2021-03-11
EP3844181B1 (en) 2025-11-12
IL280918A (en) 2021-04-29
US11884712B2 (en) 2024-01-30
AU2019328290A1 (en) 2021-02-25
KR20210070287A (en) 2021-06-14
CA3108949A1 (en) 2020-03-05
TWI851594B (en) 2024-08-11
IL280918B1 (en) 2025-06-01
US11518792B2 (en) 2022-12-06
IL280918B2 (en) 2025-10-01
US20200071374A1 (en) 2020-03-05
TW202122416A (en) 2021-06-16
US20240124544A1 (en) 2024-04-18
JP2024026248A (en) 2024-02-28
JP2021534828A (en) 2021-12-16
TW202442672A (en) 2024-11-01
KR102877278B1 (en) 2025-11-03
US20230272027A1 (en) 2023-08-31
JP7735373B2 (en) 2025-09-08
US20240124543A1 (en) 2024-04-18
AU2024287134A1 (en) 2025-01-23
EP3844181C0 (en) 2025-11-12
US20210070825A1 (en) 2021-03-11
JP2025172844A (en) 2025-11-26
AU2019328290B2 (en) 2024-10-10
EP3844181A1 (en) 2021-07-07
US12269854B2 (en) 2025-04-08

Similar Documents

Publication Publication Date Title
SG11202101779RA (en) Multi-chain chimeric polypeptides and uses thereof
IL273327A (en) Chimeric polypeptides and uses thereof
IL280920A (en) Single-chain and multi-chain chimeric polypeptides and their uses
SG11202101780WA (en) Single-chain chimeric polypeptides and uses thereof
SG11202102777PA (en) Masked cytokine polypeptides
IL279505A (en) Chimeric transmembrane proteins and uses thereof
IL289122A (en) Polypeptides
SG11202106257WA (en) Chimeric receptor polypeptides and uses thereof
IL280808A (en) Ox40-binding polypeptides and uses thereof
GB201719557D0 (en) Polypeptide
IL289119A (en) Polypeptides
ZA201906235B (en) Csf1r-based chimeric proteins
IL287782A (en) Cd33-binding polypeptides and uses thereof
GB201820556D0 (en) Novel polypeptides
GB2586518B (en) Resistor Geometry
IL281088A (en) Flt3l-based chimeric proteins
GB201819200D0 (en) Polypeptide and uses thereof
IL268170A (en) Vsig8-based chimeric proteins
GB201707139D0 (en) Polypeptides
SG11202102378WA (en) Arginase1 polypeptides
GB201810052D0 (en) Polypeptide
GB201800280D0 (en) Hypercomputation with programmable matter
GB2610886B (en) Resistor geometry
GB201906126D0 (en) Chimeric protein
HK40048557A (en) Multi-chain chimeric polypeptides and uses thereof